Lavipharm (ATH:LAVI) Moat Score: 0/10 (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATH:LAVI Lavipharm SA ATH:LAVI
82 GF Score
Price €1.64
GF Value €1.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lavipharm Moat Score?

Lavipharm has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Lavipharm has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lavipharm might have No Moat - No discernible moat.

Lavipharm  (ATH:LAVI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lavipharm Moat Score Related Terms

ATH:LAVI
82GF Score
Lavipharm SA ATH:LAVI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lavipharm (ATH:LAVI) Overvalued in 2026?

Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued. The current stock price of €1.64 is trading 37.8% above its estimated GF Value™ of €1.19. GuruFocus considers Lavipharm to be Significantly Overvalued.

Key valuation signals for ATH:LAVI:

  • Moat Score: 0
  • GF Value™: €1.19 vs. price of €1.64 (37.8% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the ATH:LAVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lavipharm Business Description

Other Exchanges BXA0:Germany
Address 12, Agias Marinas Street, PO Box 59, Paiania, GRC, 19002
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
82GF Score

Get the complete analysis for ATH:LAVI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price
€1.19
GF Value